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Breakdownoftheinnerblood-retinalbarrier(iBRB)occursearlyindiabetesandiscentraltothedevelopmentofsight-threatening
diabetic macular edema (DME) as retinopathy progresses. In the current study, we examined how advanced glycation end prod-
ucts (AGEs) forming early in diabetes could modulate vasopermeability factor expression in the diabetic retina and alter inter-
endothelial cell tight junction (TJ) integrity leading to iBRB dysfunction. We also investigated the potential for an AGE inhibitor
to prevent this acute pathology and examined a role of the AGE-binding protein galectin-3 (Gal-3) in AGE-mediated cell retinal
pathophysiology. Diabetes was induced in C57/BL6 wild-type (WT) mice and in Gal-3−/− transgenic mice. Blood glucose was
monitored and AGE levels were quantiﬁed by ELISA and immunohistochemistry. The diabetic groups were subdivided, and one
groupwas treatedwiththeAGE-inhibitorpyridoxamine(PM)whileseparategroupsofWT andGal-3−/− miceweremaintainedas
nondiabetic controls. iBRB integrity was assessed by Evans blue assay alongside visualisation of TJ protein complexes via occludin-
1 immunolocalization in retinal ﬂat mounts. Retinal expression levels of the vasopermeability factor VEGF were quantiﬁed us-
ing real-time RT-PCR and ELISA. WT diabetic mice showed signiﬁcant AGE -immunoreactivity in the retinal microvasculature
and also showed signiﬁcant iBRB breakdown (P<. 005). These diabetics had higher VEGF mRNA and protein expression in
comparison to controls (P<. 01). PM-treated diabetics had normal iBRB function and signiﬁcantly reduced diabetes-mediated
VEGF expression. Diabetic retinal vessels showed disrupted TJ integrity when compared to controls, while PM-treated diabetics
demonstratednear-normalconﬁguration.Gal-3−/− miceshowedsigniﬁcantlylessdiabetes-mediatediBRBdysfunction,junctional
disruption, and VEGF expression changes than their WT counterparts. The data suggests an AGE-mediated disruption of iBRB via
upregulation of VEGF in the diabetic retina, possibly modulating disruption of TJ integrity, even after acute diabetes. Prevention
of AGE formation or genetic deletion of Gal-3 can eﬀectively prevent these acute diabetic retinopathy changes.
Copyright © 2007 Paul Canning et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Breakdown of the inner blood-retinal barrier (iBRB) is a se-
rious pathophysiological lesion in diabetic patients and if
left untreated can lead to sight-threatening diabetic macu-
lar edema (DME), see [1, 2] .T h e r ea r ev a ri o u sa p p r o a c h e st o
quantiﬁcation of iBRB dysfunction in patients, but irrespec-
tiveofthetechniqueemployed[3,4],itisestablishedthatthis
lesion occurs early in clinical diabetic retinopathy [5] and is
associated with progression of the disease [6]. Breakdown of
the iBRB is also a feature of experimental diabetes in animal
models, being observed as early as 1-2-week postdiabetes in-
d u c t i o ni nr o d e n t s[ 7, 8].
The precise mechanism of iBRB compromise during
diabetic retinopathy remains incompletely elucidated but
there are ﬁrm links with diabetes-mediated upregulation of
the potent vasopermeability factor VEGF from the neural
retina [9]. VEGF modulates loss of tight junction integrity or
enhanced transport mechanisms in endothelial cells in the
early stages of diabetic retinopathy [10, 11]. Upregulation
of this growth factor occurs early in diabetes [12]w h i c h
suggests that expression may be linked to acute hyper-
glycemia, alteration in retinal blood ﬂow, and/or enhanced
proinﬂammatory processes inﬂuencing retinal capillary
function. Treatment of diabetic rodents with a range of
agents that either modulate protein kinase C activation [13],
prevent formation of reactive oxygen species (ROS) [14],
or regulate aldose reductase activity [15, 16]c a np r e v e n t
diabetes-mediated rises in VEGF expression and prevent
iBRB dysfunction.
Theformation of advancedglycationend products (AGEs)
is an important pathogenic mechanismindiabeticretinopathy.2 Experimental Diabetes Research
These adducts form on the amino groups of proteins, lipids,
and DNA through nonenzymatic glycation reactions with
glucose and also through highly reactive α-oxoaldehydes
such as glyoxal, (GO), methylglyoxal (MGO), and 3-
deoxyglucosone (3-DG) which can form AGEs very rapidly
[17]. In support of clinical correlates, AGE-adducts are
known to accumulate intracellularly in neurones and vas-
cular cells, and extracellularly on basement membranes of
diabetic retina [18–20] where they mediate pathophysio-
logical changes [21–23]. Advanced glycation reactions also
have relevant pathogenic eﬀects on retinal vascular cells in
vitro; responses that may, in part, be mediated through a
range of AGE-binding proteins and receptors with deﬁned
proinﬂammatory signalling capacity and ability to modulate
AGE-mediated pathophysiology [24–26].
In terms of iBRB function, AGEs are known to induce
expression of the potent vasopermability agent VEGF in the
retinainvivo[21,27],orinretinalcellsinvitro[28,29].Fur-
thermore, these adducts can disrupt endothelial junctional
complexes [30] and induce hyperpermeability in retinal cap-
illary endothelial monolayers [31]. In vivo, AGEs have been
linked to breakdown of the iBRB during diabetic retinopa-
thy through infusion of preformed, highly modiﬁed “model
AGEs”intonondiabeticanimalswhichcauseleakageofalbu-
min and concomitant increases in VEGF mRNA expression
[21, 32]. To date there have been no studies on the possibility
of preventing acute VEGF upregulation or iBRB dysfunction
usingAGEinhibitors.Therefore,inthecurrentstudywehave
examined how AGEs, formed early in diabetes, could modu-
late vasopermeability factor expression in the diabetic retina
and alter interendothelial cell tight junction integrity lead-
ing to iBRB dysfunction. Previous studies have shown a role
for galectin-3 (Gal-3) in modulation of some AGE-mediated
responses [26] therefore we have also investigated the con-
tribution of this multifunctional lectin in AGE-mediated cell
retinal pathophysiology in short-term diabetes.
2. MATERIALS AND METHODS
2.1. Animalsandinductionofdiabetes
Both Gal-3−/− and corresponding wild-type (WT) C57/BL6
controls at 6-8-week old were used in this study. All animals
were housed and cared for in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vi-
sion Research and to British Home oﬃce regulations. Gal-3
knockout mice (Gal-3−/−) were generated and backcrossed
to C57/BL6 for 9 generations as previously described by Hsu
et al. [33]. Male Gal-3−/− and WT control animals were
rendered diabetic with a single intraperitoneal injection of
streptozotocin, 165mg/kg in sterile ﬁltered citrate buﬀer pH
4.6 (Sigma Chemical Company, Poole, England) as has been
previously reported [34]. Nondiabetic WT animals were in-
jected with an equivalent volume of citrate buﬀer alone.
Blood glucose levels were measured one week postdiabetes
induction and animals with glucose readings greater than
15mmol/L were included in the study. A subset of diabetic
animals subsequently received the AGE-inhibitor pyridox-
amine(PM;pyridoxaminedihydrochloride,BiostratumInc.,
Durham, NC, USA) administered orally in the drinking wa-
ter(1g/L).Waterintakefromallmicegroupswasmonitored.
Three weeks postdiabetes induction, and immediately prior
to experimentation, animals were reweighted and blood glu-
cose levels were remeasured to conﬁrm diabetic status.
2.2. AssessmentofAGEsinretina
Three weeks postdiabetes induction, 6 animals per group
were euthanized by asphyxiation with carbon dioxide, the
eyes enucleated, and retinas dissected under an operating
microscope before being ﬂash frozen in liquid nitrogen and
stored at −80◦C. The brain and the kidneys were also re-
moved, ﬂash frozen, and stored at −80◦C. Protein was ex-
tracted by homogenising the retinal, brain, and kidney tissue
extracts, respectively, in radioimmunoprecipitation buﬀer
(RIPA; consisting of 0.5M Tris-HCl, pH 6.8 containing 10%
(w/v) SDS), over ice. Total protein was quantiﬁed by BCA as-
say (Pierce, MSC, Dublin, Ireland), and equivalent amounts
loaded for AGE quantiﬁcation by competitive ELISA using
a polyclonal antibody to carboxymethyllysine (CML) (kind
gift from Dr. Suzanne Thorpe, University of South Carolina,
Columbia, SC, USA), see [22].
2.3. Assessmentofblood-retinalbarrierbreakdown
Plasma albumin leakage from the diabetic retinal vascula-
ture and hence iBRB dysfunction were quantiﬁed in using
Evans blue in accordance with the published protocol [8]
with modiﬁcations as outlined by Brankin et al. [35]. Brieﬂy,
Evans blue dye (Sigma), was dissolved in PBS (30mg/mL),
sonicated for 5 minutes, and ﬁltered through a 0.45μmﬁ l -
ter.Nondiabetic,diabetic,andPM-treateddiabeticwild-type
and Gal-3−/− mice (n = 8/group) were anaesthetized with
isoﬂuorane and Evans blue dye intravenously administered
by tail vein injection (26g, Venisystems Ltd., Abbot Ireland
Ltd., Sligo, Eire) at a dose of 45mg/kg in a volume of 200μL
upon which mice were seen to turn blue, and this was used
asaconﬁrmationthatthedyehadbeen takeninto theblood-
stream.
Quantiﬁcation of dye leakage into the neuropile was as-
sayed as previously described [8]. Brieﬂy, 3 hours after Evan’s
blue injection the mice were perfused using citrate buﬀer at
a pressure of 120mm/Hg (for up to 2 minutes). Both eyes
were enucleated and retinas were removed. After determina-
tion of the wet weight, the retinas were completely dried by
placinginaSpeed-Vacovernightat60◦C.Retinaldryweights
were subsequently determined, and retinas then crushed in
120μL formamide at 70◦C for 18 hours, in order to remove
Evan’s blue. After this time, the extract was centrifuged with
a ﬁlter centrifuge tube at 15000rpm for 30 minutes in order
to remove retinal debris. The ﬁltrate was subsequently read
on the spectrophotometer at an absorbance of 620nm, the
absorbance maximum for Evan’s blue, and 740nm, the ab-
sorbance minimum. The concentration of dye in the extracts
was calculated from a standard curve of Evan’s blue in for-
mamide. The BRB breakdown was calculated as outlined by
Qaum et al. [8].Paul Canning et al. 3
For visual assessment of leakage, animals were deeply
anaesthetized using ketamine/xylazine and 40kd FITC-
Dextran (Sigma) (30mg/mL in sterile PBS) injected into
the left ventricle. The tracer was allowed to circulate for
∼2 minutes and the eyes were then enucleated and imme-
diately ﬁxed in 4% PFA. The eyes were ﬁxed overnight in
2% paraformaldehyde and the following day the retinas were
dissected oﬀ, cut in a Maltese cross-conﬁguration, and ﬂat-
mounted onto glass slides. The retinas were then viewed us-
ing epiﬂuorescence.
2.4. QuantiﬁcationofretinalVEGFmRNAandprotein
Animals were treated as described previously and eyes enu-
cleated immediately following sacriﬁce (n = 6/group). Reti-
nas were dissected away from the posterior eye cup and
placed in an RNA stabilisation reagent (RNAlater, Ambion,
Austin, Tex, USA) and stored at 4◦C. Total retinal RNA was
extracted with Tri-reagent (Sigma) by standard isopropanol:
chloroform precipitation as described in the manufacturer’s
instructions. The resulting RNA pellets were washed twice
with 75% ethanol, and resuspended in 30μL diethyl pyro-
carbonate (DEPC) treated water. RNA integrity and quality
were conﬁrmed by analysis of 260 : 280nm absorbance ra-
tio, and visualisation of ribosomal 28s and 18s bands on
a 1% agarose gel. cDNA was synthesized from 2μg retinal
RNA using a reverse transcriptase cDNA synthesis kit (Im-
Prom II, Promega, MSC, Dublin, Ireland) according to man-
ufacturer’sinstructionsonanautomatedAppliedBiosystems
2720 Thermal Cycler.
cDNA was diluted twenty-fold prior to PCR ampliﬁca-
tion. Real-time PCR analysis was performed for quantitative
analysis of mRNA expression. A 189bp-fragment of VEGF
cDNA was ampliﬁed with murine-speciﬁc primers (forward:
5  TTACTGCTGTACCTCCACC 3 ;r e v e r s e :5   ACAGGA-
CGGCTTGAAGATG 3 ). In addition, primers to amplify
a 100bp-fragment of the housekeeping gene 28s ribosomal
RNA were used: (forward 5  TTGAAAATCCGGGGGAGA-
G3  ; reverse 5  ACATTGTTCCAACATGCCAG 3 ). Real-
time RT-PCR was performed with an ABI Prism 7000 Se-
quence Detection system. PCR was performed in a 96-well
plate format (ABgen, Rochester, NY, USA), in a 20μLv o l -
ume, containing 0.5μMp r i m e r s ,r e a c t i o nb u ﬀer, 2.5mM
MgCl2,d N T P s ,Taq DNA polymerase (hotstart), and SYBER
greenIﬂuorescentdye(Qiagen,Crawley,UK).Ampliﬁcation
involved an initial 15-minute denaturation step, followed by
up to 45 cycles of a 95◦C denaturation for 15 seconds, 52–
58◦C annealing for 20 seconds, and 72◦C for an appropriate
extension time (5–25 seconds). Fluorescence of the green dye
that was bound to the PCR product was detected at the end
of each extension period and the speciﬁcity of the ampliﬁca-
tion reactions conﬁrmed by melting curve analysis and sub-
sequent agarose gel electrophoresis. PCR ampliﬁcation reac-
tions were performed in triplicate on material from at least
two independent reverse transcription reactions. Quantiﬁca-
tion data was analysed by the delta Ct method [36], and nor-
malised to the housekeeping gene 28s ribosomal RNA.
ForVEGFproteinquantiﬁcation,retinaswerefreshlydis-
sected, and placed in 200μLR I P Ab u ﬀer supplemented with
protease inhibitor cocktail (Roche, Mannheim, Germany).
Retina was homogenised with a plastic pestle and hand held
battery rotor, and sonicated. The lysate was centrifuged at
13000rpm for 5 minutes, and the resulting supernatants as-
sayed for VEGF activity using the Quantikine Mouse VEGF
Immunoassay kit (R&D Systems) as per the manufacturer’s
instructions.
2.5. Immunohistochemistry
The retinal vasculature was visualised by reaction with bi-
otinylated isolectin B4 from Griﬀonia Simplicifolia (Sigma-
Aldrich Ltd., Gillingham, UK) at 50ng/mL followed by
streptavidin-Alexa 568 (Molecular Probes Europe BV, Lei-
den, Netherlands). Retinal ﬂatmounts were washed exten-
sively and mounted in Vectasheild (Vector Laboratories Ltd.,
Peterborough,UK).ImageswereacquiredusinganOlympus
BX60 ﬂuorescence microscope (Olympus UK Ltd., London,
UK) ﬁtted with a MicroRadiance confocal scanning laser
microscope (CSLM) (Bio-Rad Laboratories, Hercules, Calif,
USA).
For methylglyoxal (MG)-derived AGE immunolocaliza-
tion, one eye from 5 animals from each treatment regime
was ﬁxed in 4% PFA for 4 hours and then washed ex-
tensively over a 4-hour period after which the anterior
segment-lens complexes were removed and the posterior
eye cups relaxed by placing 4 radial cuts from the reti-
nal periphery to points within 1mm from the optic disc.
The posterior eye cups were permeabilised and nonspe-
ciﬁc immunoreactive sites blocked for 16 hourrs at 4◦Ci n
PBS containing 0.5% Triton X-100 (TX-100), 5% normal
goat serum and mouse-on-mouse reagent (Vector Laborato-
ries, Youngstown, Ohio, USA). Monoclonal anti-MG mod-
iﬁed protein antibody (kindly donated by Dr. Ryoji Na-
gai, Kumamoto University, Kumamoto, Japan) or control
mouse IgG (Sigma) was added to the retinas overnight at
4◦C at 1 : 1000 dilution in PBS containing 0.5% TX-100.
The retinas were then blocked in 5% NGS in permeabilis-
ing buﬀer, washed extensively, and exposed to antimouse-
488nm Alexa (Molecular Probes Inc., Eugene, Ore, USA),
diluted 1 : 500 in PBS containing TX-100 for 3 hours at
4◦C. The retinas were then washed extensively, mounted in
Citiﬂuor (Agar Scientiﬁc Ltd., Essex, England) on micro-
scope slides and immunoﬂuorescence detected by CSLM.
Gain settings were kept constant between specimens dur-
ing digital confocal image capture, in order to compare the
intensity of immunoreactivity in the retina between treat-
ment groups.
For occludin immunolocalization, 5 eyes from animals
fromeachtreatmentgroupwereenucleatedandﬁxedin70%
e t h a n o lf o r3 0m i n u t e sa t4 ◦C. Following this initial ﬁxation,
eyes were transferred to acetone that had been prechilled at
−20◦C, and ﬁxed for further 3 minutes. Retinas were dis-
sected, blocked, and permeabilised with blocking reagent
(PBS, 0.5% Triton X-100, and 5% goat serum) overnight at
4◦C, prior to incubation with mouse antioccludin primary
antibody (Zymed Laboratories, South San Francisco, Calif,
USA) (1 : 3000 dilution in blocking reagent) for two days4 Experimental Diabetes Research
Table 1: Metabolic parameters and AGE accumulation in tissues from diabetic (DB) and nondiabetic (NDB) mice. Blood glucose levels are
signiﬁcantly higher in the diabetic groups when compared to nondiabetic controls. There is no diﬀerence between WT and Gal-3−/− mice,
nordoespyridoxamine(PM)haveanyeﬀectonhyperglycaemia.DiabeticWTandGal-3−/− micealsoshowcharacteristiclossofweightwhen
compared to their respective nondiabetic counterparts. Retinal CML-immunoreactivity is elevated in WT diabetic mice when compared to
nondiabetic controls (P<. 05). Nondiabetic Gal-3−/− animals have signiﬁcantly less retinal CML when compared to WT control and PM has
noappreciableinﬂuenceonCMLaccumulationoverthis2-weektimeframe.Asreferencetissues,kidneyandbrainCML-immunoreactivities
are elevated in diabetes in WT and Gal-3−/− mice (± standard deviation).
CML (pg CML/mg protein)
Weight Blood glucose Brain Kidney Retina
WT NDB 27.5 ±2.08 15.85 ±5.44 58.73 ± 8.64 299.57 ±86.0 81.77
WT DB 19.15 ± 2.87∗ 30.99 ±5.97∗∗ 60.60 ± 6.26 341.28 ±137.63 87.42∗
WT DB PM 19.10 ± 4.51∗ 28.23 ±8.26∗∗ 60.29 ± 8.54 348.29 ±115.44 89.65∗
Gal-3−/− NDB 24.24 ±1.97 12.46 ±4.78 64.13 ± 3.98 386.19 ±135.17 72.09∗
Gal-3−/− DB 22.14 ±2.07 30.46 ±4.05 69.66 ± 4.99 310.79 ±224.41 87.18
Gal-3−/− DB PM 20.50 ±1.78 28.76 ±6.11 66.45 ± 5.68 281.73 ±48.90 89.14
∗P<. 05.
∗∗P<. 001.
at 4◦C. Retinas were washed six times in PBS and incubated
with a goat antimouse Alexa 488nm secondary antibody
(1 : 2000dilutioninblocksolution)(Invitrogen,Paisley,UK)
for 2 hours at room temperature. Retinas were washed for
further six times in PBS (20 minutes each, as previously) be-
fore ﬂat mounting on microscope slides by making four ra-
dialcutsinaMaltesecross-conﬁguration.Flat-mountedreti-
nas were visualised using CSLM as outlined above.
3. RESULTS
3.1. DiabetesandformationofAGEs
Blood glucose levels were elevated in the diabetic groups
when compared to nondiabetic (P<. 001) and there was
no diﬀerence between WT and Gal-3−/− groups (Table 1).
PM had no signiﬁcant inﬂuence on hyperglycaemia in either
Gal-3−/− or WT mice (Table 1). Diabetic WT and Gal-3−/−
also exhibited characteristic loss of weight when compared
to their respective nondiabetic counterparts (Table 1).
As determined by competitive ELISA, CML levels were
modestly but signiﬁcantly elevated in the retinas of WT dia-
beticmicewhencomparedtonondiabeticcontrols(P<. 05).
Nondiabetic Gal-3−/− animals had signiﬁcantly less retinal
CML when compared to WT control (P< .05). Diabetes in-
creased this CML-immunoreactivity in Gal-3−/− animals. In
all cases, PM had no appreciable inﬂuence on this parame-
ter (Table 1). For reference, kidney and brain from animals
recruited to this study were also assessed for AGEs. It was
determined that CML was elevated in diabetes in WT and
Gal-3−/− mice. In kidney, absence of Gal-3 reduced the CML
content after 3-week diabetes (P<. 05).
Isolectin staining showed the microvascular tree in the
retinal ﬂatmounts (Figures 1(a) and 1(b)). Immunohisto-
chemistry using a monoclonal antibody that recognises MG-
derived adducts showed localization to the intraretinal mi-
crovasculature,bothintermsofthesuperﬁcialanddeepcap-
illary plexi. In all diabetic mice examined there was marked
increase in vascular staining when compared to nondia-
betic controls (compare Figure 1(c) with Figure 1(d)). PM-
treatment reduced this MG-adduct immunoﬂuorescence
(Figure 1(e)) and in all controls (in which mouse-on-mouse
blockwasused)negativestainingwasobserved(Figure 1(f)).
3.2. Blood-retinalbarrierfunction
BreakdownoftheBRBasdeterminedbyEvansbluedyeleak-
age, was up to 4-fold greater after 2-week diabetes in WT
mice compared to nondiabetic controls (P<. 005). PM-
treatment of diabetic animals signiﬁcantly prevented this va-
sopermeability response, to the extent that there was no sig-
niﬁcant diﬀerence between nondiabetic and PM-treated dia-
betic WT mice (Figure 2). Gal-3−/− mice failed to demon-
strate any diabetes-mediated increase in BRB dysfunction
which contrasted markedly with their WT counterparts
(Figure 2).
3.3. Tightjunctionintegrity
Leakage of FITC-dextran of 40kd was evident in diabetic
retinas while nondiabetic controls showed no leakage of this
tracer (compare Figures 3(a) and 3(b)). Diabetes also had
ap r o f o u n de ﬀect on integrity of tight junctions, as deter-
mined by immunolocalization of the junctional complex
component protein occludin in retinal ﬂatmounts. Im-
munostaining for occludin-1 demonstrated integrity of the
tight junctions between arterial, capillary, and venous en-
dothelium in the nondiabetic WT animals (Figure 3(c)).
Diabetes signiﬁcantly altered this conﬁguration, with less
deﬁned occludin-immunoreactivity in TJ complexes, show-
ing a cytoplasmic staining pattern rather than being lo-
calised at the plasma membrane (Figure 3(e)). PM treat-
ment seemed to restore some of this integrity in diabetic an-
imals (Figure 3(g)). In contrast to WT counterparts, the reti-
nal microvasculature of Gal-3−/− demonstrated integrity of
tight junctions, not only in nondiabetic controls but also inPaul Canning et al. 5
(a) (b)
(c) (d)
(e) (f)
Figure 1: AGE accumulation in the diabetic retina. Lectin staining
shows the vascular tree in (a) nondiabetic and (b) diabetic animals.
At such an acute time frame of diabetes, there is no appreciable dif-
ference in density of capillaries. Also on retinal ﬂat mounts, an anti-
body that recognizes MG-derived AGEs shows modest immunore-
activity in the retinal-microvasculature in nondiabetic mice (c).
Diabetic mice (d) show considerably more intense AGE labelling,
again largely within the retinal-blood vessels which are only par-
tially reduced in diabetics treated with PM (e). Controls show only
background immunoreactivity (f). Original magniﬁcation x200.
diabetic and nondiabetic animals treated with PM (Figures
3(d), 3(f),a n d3(h)).
3.4. VEGFexpression
ELISA showed that after only two weeks of diabetes in WT
mice VEGF peptide was increased twofold over nondiabetic
controls (P<. 01) (Figure 4(a)). PM-treatment showed a
signiﬁcant, albeit incomplete, reduction in this diabetes-
mediated increase (P<. 05). The Gal-3−/− animals had a
much lower baseline level of VEGF when nondiabetic WT
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Figure 2: Inner blood-retinal barrier (iBRB) function in diabetic
WT and Gal-3−/− mice. As determined by Evan’s blue assay, di-
abetic animals (DB) show a signiﬁcant increase in BRB dysfunc-
tion when compared to nondiabetic (NDB) controls. Pyridoxamine
(PM)treateddiabeticanimalsdonotshowthisvasopermeabilityre-
sponse and are more comparable to nondiabetic controls. Gal-3−/−
fails to demonstrate diabetes-induced barrier dysfunction.
was compared with the transgenic counterpart (P<. 001).
VEGF levels were increased upon induction of diabetes in
the Gal-3−/− mice and while the magnitude of change was
comparable to WT, the VEGF levels in Gal-3−/− were still
lower than nondiabetic WT. PM treatment of Gal-3−/− di-
abetic mice increased VEGF relative to diabetic counterparts
(P<. 01) (Figure 4(a)).
For all relative mRNA expression data, data was nor-
malised to the housekeeping gene ribosomal 28s, and re-
sults were expressed relative to the levels in the WT non-
diabetic control group. VEGF mRNA ﬂuctuation correlated
closely with the trend seen for Evans blue leakage between
the various treatment groups of animals. VEGF mRNA ex-
pression was almost three-fold higher in the untreated WT
diabetic control group compared to the nondiabetic controls
(P<. 01) (Figure 4(b)). PM treatment reduced this increase
in diabetic VEGF mRNA levels (P<. 05). In the correspond-
ing Gal-3−/− animals, the diabetes-induced increase in reti-
nal VEGF mRNA expression was less pronounced than in
WT.Nevertheless,PMtreatmentdecreasedtheVEGFmRNA
expression levels to less than those measured in the nondia-
betic control animal group (P<. 01) (Figure 4(b)).
4. DISCUSSION
Breakdown of the iBRB is an established lesion in clinical
diabetes. Abnormal microvascular leakage can occur early
after establishment of diabetes although it remains uncer-
tain how this relates to more severe, sight-threatening mac-
ular oedema. For study of iBRB dysfunction in experimental6 Experimental Diabetes Research
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 3: Diabetes alters tight junction integrity in retinal capillar-
ies. Fluorescein dextran angiography on retinal ﬂat mounts shows
integrity of the retinal microvasculature in nondiabetic mice (a)
while there is a clear leakage of tracer (∼40kd) into the retinal neu-
ropile in 2-week diabetic animals (b) (original magniﬁcation x100).
Fluorescent immunostaining for occludin-1 of retinal ﬂat mounts
from nondiabetic WT mice demonstrates plasma membrane local-
ization at the tight junctions (TJs) of the endothelium (c). By con-
trast with diabetic animals, there is aggregation of occludin-1 in
the cytoplasm of endothelial cells rather than at the plasma mem-
brane (e). PM treatment of diabetic mice only partially prevents
disruption of the junctional integrity (g). Nondiabetic (d), diabetic
(f), and PM-treated Gal-3−/− mice (h) show none of the diabetes-
induced changes observed in WT counterparts (original magniﬁca-
tion x200).
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Figure 4:VEGFproteinandmRNAexpressionindiabeticGal-3−/−
and WT mouse retina. In WT mice (black bars) VEGF expression
is signiﬁcantly increased in diabetic (DB) retina—in terms of both
protein (a) and mRNA expression (b) when compared to nondi-
abetic controls (NDB). PM-treatment signiﬁcantly reduces VEGF
expression in diabetic mice. In Gal-3−/− mice (white bars), retinal
expression levels are not as dramatically increased by the presence
of diabetes as evidenced in WT mice.
diabetes most focus has been placed on short-term retinopa-
thy models in rodents where acute phase vasopermeability
is evident after only 2-3-week diabetes [7, 8]. Various studies
haveshownthatmanipulationofadhesionmolecules,proin-
ﬂammatory cytokines, and nitric oxide can prevent this le-
sion within an acute time frame [7, 8, 37, 38]. The current
study has demonstrated that AGE inhibition by PM, soon af-
ter diabetes induction, also prevents iBRB dysfunction with
concomitant VEGF upregulation and loss of tight junction
integrity.
Advanced glycation is an important pathogenic factor in
diabetic retinopathy and most other vascular complicationsPaul Canning et al. 7
of diabetes [39]. AGE-modiﬁcations are usually consid-
ered to take months or years to accumulate in diabetic
tissues, but it is now clear that these adducts can also
form rapidly during hyperglycaemia [19]. Exposure of
retinal glial and vascular cells to high glucose in vitro can
induce signiﬁcant AGE formation after 7–10 days [40, 41],
leading to modiﬁcations that have profound pathogenic
consequences [41–43]. Hyperglycaemia-linked formation
of highly reactive α-oxaloaldehydes is a major source of
these rapidly formed intra- and extracellular adducts such as
Nε-(carboxymethyl)lysine (CML), Nε-(carboxyethyl)lysine
(CEL), and MG-derived hydroimidazolone [17]. Indeed,
MG is raised in serum from diabetic patients [44]a n d
the immunolocalization data in the current study suggests
that AGEs derived from this dicarbonyl also accumulate
in the retinal microvasculature of acutely diabetic mice.
MG-derived AGEs have been shown to occur in retinal
microvascular endothelial cells exposed for 10 days to high
glucose in vitro which is within the time boundaries of the
current in vivo study [40]. MG-modiﬁcations have been
shown to induce profound cell responses such as altering
transcriptional regulation of vasoactive growth factors [41].
MG-modiﬁcations of the basement membrane also induce
dysfunctional responses in retinal microvascular endothelial
cells [45] and it is reasonable to assume that rapid formation
of both intracellular and extracellular MG-modiﬁcations in
vivo has pathogenic implications for endothelial dysfunction
and iBRB compromise during acute diabetes.
Inhibitors of advanced glycation have shown eﬃcacy in
reducing retinal microvascular lesions in diabetic animal
models [22, 23, 46]. With direct relevance to the current
study, PM has been shown to have beneﬁcial eﬀects by pre-
venting CML formation and subsequent lesion formation
in diabetic retinopathy in a rat model over a 7-month time
frame [22]w i t ha ne ﬃcacy that is comparable to other di-
abetic complications [47]. We have now demonstrated that
PM is also eﬀective against iBRB dysfunction within an acute
treatment regime. The mechanism of this action is proba-
bly linked to the ability of PM to prevent MG-derived AGE
formation as evidenced by the present immunohistochem-
istry data in combination with previous studies that have
demonstrated PM eﬃcacy against MG-derived AGEs [48].
Perhaps unsurprisingly there was no eﬀect of PM treatment
on non-MG-derived CML formation over this short time
frame in retina, kidney, or brain which contrasted with pre-
viously reported long-term outcomes [22]. It is interest-
ing that PM could have short-term beneﬁt over a signiﬁ-
cant diabetic retinopathy lesion and, while more investiga-
tion is required, this could indicate applicability for anti-
AGE strategies over a shorter time frame than previously
thought.
AGEs have been linked to increases in retinal VEGF ex-
pression although the precise mechanism for this remains
uncertain [49]. Since the major sources of VEGF expres-
sion in the retina are Muller glia and ganglion cells it would
seem that these cells are inﬂuenced by AGE adducts either
through endogenous formation or as a response to expo-
sure from leaked AGE-modiﬁed serum proteins. We have
previously shown that Muller glia and ganglion cells accu-
mulate AGE adducts (CML) over 7-month diabetes [22],
but following more acute exposure to hyperglycaemia it is
possible that these cells could form signiﬁcant AGEs and re-
spond by upregulating VEGF. MG-modiﬁcation of the tran-
scriptional corepressor protein mSin3A has been shown as
the mechanism whereby retinal levels of the growth factor
angiopoietin-2 are upregulated in Muller glia in vitro [41].
It is interesting that most of the MG-derived protein modiﬁ-
cations in the inner retina were vascular-localised with lesser
immunoreactivity in the Muller glia. The reason for this is
unclear but it is possible that acute hyperglycaemia has most
immediate impact on the endothelium and that longer peri-
ods of high glucose exposure are required to raise intracel-
lular levels of AGEs in the retinal neuropile. The chemical
nature, time frame of formation, and cellular localization of
variousAGEsareimportantparameterstoestablishandsuch
studies are currently ongoing in our laboratory.
The current investigation indicates that iBRB dysfunc-
tion in diabetes is modulated by the presence of Gal-3. This
multifunctional protein has a diverse range properties linked
to its carbohydrate binding capacity and may be involved in
immuneprocessesandneoplastic disease[50].Gal-3alsohas
AGE-binding properties and several diabetes-related patho-
physiological responses are mediated, at least in part, by Gal-
3 (also referred to as AGE-R3 [51]). The role of Gal-3 as an
AGE-binding protein with links to diabetic microvasculopa-
thy has been previously demonstrated [52–54] and this pro-
teinalsoplaysasigniﬁcantroleinAGE-relatedpathophysiol-
ogy during diabetic retinopathy. We have previously demon-
strated that Gal-3−/− mice or neutralisation with a Gal-3 an-
tibody reversed the inhibition of retinal angiogenesis by di-
a b e t i cs e r ao re x o g e n o u sA G E s[ 26]. The presence of Gal-3
appears to be required for iBRB dysfunction during acute di-
abetes where it may modulate cell responses to AGEs. How
this occurs is uncertain, especially when one considers that
exogenous AGEs (whether occurring as modiﬁed serum pro-
teins or as substrate-immobilized cross-links) are not signiﬁ-
cantlydiﬀerentin2-weekdiabeticsandnondiabeticcontrols.
It remains possible that Gal-3 could alter vascular cell func-
tion independent of AGE binding or that the protein could
bind to intracellular adducts illicit cell stability against AGE-
induced changes.
It is entirely possible that Gal-3 could modulate barrier
dysfunction during diabetes by mechanisms that are addi-
tional to, or distinct from, AGE binding. Beyond an AGE
binding role, various possibilities can be suggested for Gal-
3 modulation of iBRB dysfunction in diabetes. Gal-3 binds
many substrate proteins including collagen IV, ﬁbronectin,
and elastin and is a main element in promoting cell adhe-
sion [50]. It is also interesting to note that this protein has a
distinct role in immune responses and it has been shown to
promote mast cell activation and proinﬂammatory signals in
a number of tissues, characterised by promoting adhesion of
neutrophils and monocytes to endothelial cells [50, 55]. In-
deed, Gal-3−/− mice show reduced inﬂammatory responses
during peritonitis [56] while macrophages from these an-
imals have attenuated phagocytic capacity when compared8 Experimental Diabetes Research
to wild-type controls [57]. iBRB compromise in diabetic
retinopathy is not necessarily separate from these proin-
ﬂammatory processes, indeed, during diabetes the retinal
microvasculature shows enhanced expression of endothe-
lial ICAM-1/VCAM-1 adhesion molecules and promotion
of capillary leukostasis [37, 38]. AGEs have been shown to
promote these responses in the murine retina [21, 32]. In-
vestigations into the links between Gal-3, retinal capillary
leukostasis, and iBRB dysfunction are ongoing. More re-
search needs to be conducted on Gal-3 and its ability to reg-
ulate pathogenic responses in diabetic retinopathy, perhaps
with respect to interaction with the well-characterised AGE
receptor RAGE [54].
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